Prime Medicine (PRME) Reports Q1 EPS

Prime Medicine, Inc. (NASDAQ:PRME) is one of the 10 Best Penny Stocks to Buy Before They Explode.

On May 7, 2026, Prime Medicine, Inc. (NASDAQ:PRME) reported Q1 EPS of (28c), versus the consensus estimate of (25c). Revenue totaled $856,000, versus the consensus estimate of $844,220. Chief Executive Officer Allan Reine said that the company continues to execute on a focused strategy aimed at advancing the potential of Prime Editing. Reine added that Prime Medicine remains on track to file regulatory applications for PM577 in Wilson Disease during the first half of the year and for PM647 in alpha-1 antitrypsin deficiency mid-year, with initial data from both programs expected in 2027. Reine also said the company continues progressing toward a potential BLA filing for PM359, which is being developed as a one-time therapy for chronic granulomatous disease. According to Reine, Prime Medicine, Inc. (NASDAQ:PRME) believes its strengthened leadership team and disciplined capital allocation strategy position the company to continue advancing its broader pipeline.

Prime Medicine (PRME) Reports Q1 EPS

Last month, Prime Medicine, Inc. (NASDAQ:PRME) announced the appointment of Svetlana Makhni as Chief Financial Officer. Makhni will oversee the company’s financial operations and strategy, including investor relations, financial planning and analysis, and corporate development.

Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company developing genetic medicines using Prime Editing technology.

While we acknowledge the risk and potential of PRME as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PRME and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.